A detailed history of Credit Suisse Ag transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 34,162 shares of KROS stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,162
Previous 26,642 28.23%
Holding current value
$1.56 Million
Previous $1.06 Million 113.5%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$41.26 - $70.48 $310,275 - $530,009
7,520 Added 28.23%
34,162 $2.26 Million
Q4 2023

Feb 08, 2024

BUY
$27.12 - $41.05 $49,982 - $75,655
1,843 Added 7.43%
26,642 $1.06 Million
Q3 2023

Nov 13, 2023

SELL
$31.57 - $43.02 $68,917 - $93,912
-2,183 Reduced 8.09%
24,799 $790,000
Q2 2023

Aug 11, 2023

BUY
$37.26 - $51.01 $287,311 - $393,338
7,711 Added 40.01%
26,982 $1.08 Million
Q1 2023

May 10, 2023

BUY
$41.44 - $59.32 $77,824 - $111,402
1,878 Added 10.8%
19,271 $822,000
Q4 2022

Feb 13, 2023

BUY
$39.45 - $51.77 $293,744 - $385,479
7,446 Added 74.86%
17,393 $835,000
Q3 2022

Nov 10, 2022

SELL
$27.8 - $40.12 $118,650 - $171,232
-4,268 Reduced 30.02%
9,947 $374,000
Q2 2022

Aug 12, 2022

BUY
$26.03 - $67.04 $143,165 - $368,720
5,500 Added 63.11%
14,215 $393,000
Q1 2022

May 16, 2022

BUY
$42.12 - $59.36 $37,739 - $53,186
896 Added 11.46%
8,715 $473,000
Q4 2021

Feb 14, 2022

SELL
$36.95 - $62.89 $20,692 - $35,218
-560 Reduced 6.68%
7,819 $458,000
Q3 2021

Nov 12, 2021

BUY
$29.27 - $43.71 $351 - $524
12 Added 0.14%
8,379 $332,000
Q2 2021

Aug 16, 2021

BUY
$42.4 - $70.11 $88,446 - $146,249
2,086 Added 33.21%
8,367 $356,000
Q1 2021

May 14, 2021

SELL
$54.0 - $75.28 $482,328 - $672,400
-8,932 Reduced 58.71%
6,281 $386,000
Q4 2020

Feb 12, 2021

BUY
$36.0 - $82.74 $547,668 - $1.26 Million
15,213 New
15,213 $1.07 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.